Table 1.
Baseline characteristics of participants by study arm, the SURfit study (N = 151).
| Control group | Intervention group | |
|---|---|---|
| (N = 75) | (N = 76) | |
| Age at baseline, mean years (SD) | 29.3 (8.7) | 31.5 (8.3) |
| Sex | ||
| Male | 42 (56%) | 43 (57%) |
| Female | 33 (44%) | 33 (43%) |
| Diagnosis | ||
| Leukaemias | 31 (41%) | 24 (32%) |
| Lymphomas | 14 (19%) | 18 (24%) |
| CNS tumours | 6 (8%) | 11 (14%) |
| Bone tumours & soft tissue sarcomas | 6 (8%) | 10 (13%) |
| Other tumoursa | 18 (24%) | 13 (17%) |
| Age at first diagnosis, mean years (SD) | 7.3 (4.6) | 7.6 (5.1) |
| Time since first diagnosis, mean years (SD) | 22.0 (9.2) | 24.0 (8.6) |
| Relapse of primary cancer | 6 (8%) | 8 (11%) |
| Subsequent primary cancer | 3 (4%) | 4 (5%) |
| Received surgery | ||
| No surgery | 35 (47%) | 30 (39%) |
| 1 surgery | 30 (40%) | 36 (47%) |
| ≥2 surgeries | 10 (13%) | 10 (13%) |
| Received chemotherapy | 67 (89%) | 69 (91%) |
| Received anthracyclines | 51 (68%) | 45 (59%) |
| Total cumulative dose (mg/m2), mean (SD)b | 193.9 (97.8) | 191.7 (89.3) |
| Received steroids | 45 (60%) | 42 (55%) |
| Total cumulative dose (mg/m2), mean (SD) | 4442.5 (3171.9) | 4045.8 (3431.1) |
| Received radiotherapy | ||
| No radiotherapy | 45 (60%) | 45 (59%) |
| Total body irradiation | 2 (3%) | 3 (4%) |
| Cranial radiotherapy | 15 (20%) | 12 (16%) |
| Abdominal radiotherapy | 7 (9%) | 5 (7%) |
| Other location | 6 (8%) | 11 (14%) |
| Received cranial irradiation ≥24 Gy | 10 (13%) | 10 (13%) |
| Received stem cell transplantation | 4 (5%) | 5 (7%) |
CNS central nervous system, Gy grey, N/n number, SD standard deviation.
There was no missing information for all baseline characteristics, except 4 participants who received steroids had missing information on cumulative steroid dose (3 participants of the control group and 1 participant of the intervention group).
aOther tumours included: neuroblastoma (n = 6), retinoblastoma (n = 4), renal tumours (n = 8), hepatic tumours (n = 1), germ cell tumours (n = 3), other and unspecified malignant neoplasms (n = 2), Langerhans cell histiocytosis (n = 7).
bDoxorubicin isotoxic equivalent dose.